Treatment of previously untreated patients with chronic HCV genotype 1 infection with boceprevir in German real-life: high end of treatment response of 95% in patients with early…
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: The achievement of early virologic response (EVR) during triple therapy of chronic HCV genotype 1 infection with the HCV protease inhibitor boceprevir has been identified as predictor to shorten treatment to 24 weeks. The present interim analysis of the NOVUS observational study was aimed to determine the frequency of EVR during boceprevir triple therapy in German real-life and to determine the virologic outcome of patients with and without EVR. Methods: From April 2012 until January 2014, 536 patients (pts) with genotype 1 infection were recruited in the ongoing NOVUS study by 97 practices and hospi…
